Patent 10,881,659 scope, claim-by-claim coverage, and US heavy menstrual bleeding IP landscape
US Drug Patent 10,881,659 claims combination oral regimens for heavy menstrual bleeding (HMB), using an orally administered 4-((R)-2-(substituted pyrimidinyl)-1-phenylethylamino)butyric acid sodium salt at a defined 600 mg/day (free-acid equivalent) exposure plus estradiol 1.0 mg/day and norethindrone acetate 0.5 mg/day, with efficacy thresholds tied to menstrual blood volume and additional limitations tied to duration and safety outcomes (bone mineral density loss). The estate is framed as method claims, including regimen duration, fibroid vs non-fibroid populations, dosing schedules, and dosage-form splitting into separate daily units.
What is US Patent 10,881,659 and what does it claim?
Core claimed invention (representative claim 1):
A method of managing HMB in a subject by orally administering for ≥84 days:
- (a) Investigational active: the sodium salt of a specific (R)-configured substituted butyric acid compound (defined by a long chemical structure), dosed as 600 mg/day equivalent of free acid, split as ~300 mg AM + ~300 mg PM; and
- (b) estradiol 1.0 mg/day; and
- (c) norethindrone acetate 0.5 mg/day;
with a response requirement that the method reduces menstrual blood loss to <80 mL per cycle and by ≥50% from baseline.
Key claim architecture:
- Method claims (not composition claims), so enforceable conduct is tied to how the drug regimen is used (dose, schedule, duration, population, and outcome).
- Combination includes a targeted small-molecule sodium salt plus two hormone components at fixed doses.
How broad are the method claims in 10,881,659 (dose, schedule, duration, and endpoints)?
Claim breadth drivers
1) Dose and salt form specificity
The active is not described generically. Claim 1 locks in:
- The compound identity via the recited chemical definition.
- Sodium salt form.
- Total exposure: 600 mg/day free-acid equivalent.
- Split dosing in claim 1: twice daily ~300 mg + ~300 mg.
Impact: A design-around can target:
- different salt form,
- different total daily exposure,
- different splitting schedule (though later claims recast daily dosing forms).
2) Duration threshold and timing windows
- Claim 1: at least 84 days.
- Claim 2: at least 168 days.
- Claim 3: ~168 days to ~1 year.
Later fibroid claims set additional duration ceilings:
- Claim 8: ≥84 days to ~168 days.
- Claim 11: ≥84 to ~168 days.
- Claim 16: as needed not to exceed 24 months.
Impact: A generic developer can attempt to launch with shorter treatment windows, but the estate spans multiple duration “bands,” and later claims include “as needed” continuation up to 24 months.
3) Outcome-based limitations (response thresholds)
Multiple claims require:
- menstrual blood loss <80 mL per cycle
- ≥50% reduction from baseline
Impact: These are “use” limitations that can be litigated through clinical outcome proof (and can raise evidentiary issues for both sides), but they also narrow the covered population behavior to successful management regimens.
4) Population qualifiers (fibroids and non-fibroids)
- Claim 4: subject has uterine fibroids.
- Claim 5: subject does not have uterine fibroids.
- Claim 6: in the non-fibroid group, subject has adenomyosis.
Claims 7-16 focus on HMB associated with uterine fibroids, which narrows the method context.
Impact: Even if a product is indicated for fibroid-associated HMB, claim coverage depends on whether the method is practiced in the relevant subpopulation as defined in the claim.
5) Hormone scheduling flexibility
- Claim 1: estradiol and norethindrone acetate are part of the regimen but not explicitly tied to once vs twice daily scheduling within claim 1.
- Claim 7: estradiol and norethindrone acetate are explicitly once daily.
- Claim 9: estradiol/norethindrone are administered simultaneously with either the first or second dose of the sodium salt.
Impact: This matters for label design and pharmacy switching patterns. If clinical practice separates hormone dosing from the timing used to coordinate with the sodium salt doses, it can fall outside certain dependent claims (but claim 1 may still remain relevant).
6) Dosage-form splitting into AM/PM units (independent regimen form claim 10)
Claim 10 creates a dosage-form structure:
- A first dosage form containing 300 mg free-acid equivalent of the sodium salt plus 1.0 mg estradiol and 0.5 mg norethindrone acetate, once daily, AM.
- A second dosage form containing 300 mg of the sodium salt, once daily, PM.
- Both dosage forms administered daily in approximately morning/evening.
Impact: This claim can target specific commercial product packaging/administration patterns. Even if the active dosing is the same, splitting into distinct dosage forms as claimed can be necessary to land in claim 10.
7) Bone mineral density protection thresholds (dependent claims 12 and 15)
- Claim 12 adds: regimen “limits bone mineral density loss from baseline” to <8%.
- Claim 15 tightens: bone mineral density loss <5%.
Impact: This creates a strong safety-performance limitation that may be used to distinguish clinical practice and label-supported regimen targets. If real-world or study data show higher loss than the threshold, it may affect whether the method satisfies the claims. If data consistently show lower loss, it reinforces enforceability.
What are the claim-by-claim scope boundaries in 10,881,659?
Claim 1: baseline broadest combination method
Enforces:
- Oral regimen ≥84 days
- Sodium salt of the specified compound
- 600 mg/day free-acid equivalent, 300 mg + 300 mg
- Estradiol 1.0 mg/day
- Norethindrone acetate 0.5 mg/day
- Efficacy: <80 mL per cycle and ≥50% reduction
Claim 2 and 3: longer duration variants
- Claim 2: ≥168 days
- Claim 3: ~168 days to ~1 year
Claim 4-6: population pivots
- Claim 4: uterine fibroids
- Claim 5: no uterine fibroids
- Claim 6: in non-fibroid subjects, adenomyosis
Claim 7: fibroid-associated HMB with explicit once-daily hormones
- Focus: HMB associated with uterine fibroids
- ≥84 days
- Sodium salt unchanged: 600 mg/day split doses (AM/PM implied by claim 7 “twice daily” structure)
- Estradiol 1.0 mg/day once daily
- Norethindrone acetate 0.5 mg/day once daily
- Same efficacy endpoints
Claim 8: mid-duration window for fibroids
Claim 9: synchronization limitation
- Estradiol and norethindrone acetate administered simultaneously with the first or second sodium-salt dose
Claim 10: split dosage-form regimen
Enforces regimen as administered via two dosage forms:
- AM unit: includes 300 mg sodium salt equivalent + estradiol 1.0 mg + norethindrone acetate 0.5 mg
- PM unit: includes 300 mg sodium salt equivalent only
- Each unit administered once daily (AM and PM)
Claim 11: duration for claim 10
Claim 12: fibroid-associated regimen with bone density limitation
- Same tri-drug regimen structure as claim 7 (including sodium salt split dosing)
- Bone mineral density loss limited to <8% from baseline
Claim 13: duration for claim 12
Claim 14: synchronization for claim 12
- Hormones administered simultaneously with first or second sodium-salt dose
Claim 15: tighter bone density limitation
- Bone mineral density loss <5%
Claim 16: “as needed” continuation ceiling
- Continue oral tri-drug regimen for time “as needed” to manage fibroid-associated HMB
- Not to exceed 24 months
How does 10,881,659 compare with other US HMB patent patterns (method vs composition, and combo vs single-agent)?
HMB patent landscapes often split into:
- single-agent hormonal approaches (e.g., progestins, GnRH modulators),
- procedural/device approaches,
- combination or regimen claims targeting both bleeding control and adverse-effect mitigation.
US 10,881,659 is a tri-drug oral regimen patent with response and safety outcome constraints, and with at least one claim emphasizing dosage-form splitting. That structure is materially different from patents that only claim:
- a composition of matter (active alone or in a fixed-dose combination), or
- a pharmacokinetic range, or
- a general “treat HMB” statement without quantifying response or BMD loss.
What does the patent likely cover commercially (label-like regimen behavior)?
Even without relying on external text, the claim set implies real-world regimen features:
- A daily regimen for at least 84 days.
- A defined total daily exposure (600 mg/day sodium salt equivalent) given in two administrations (300 mg AM, 300 mg PM), plus once-daily hormones.
- A dosing strategy that can be packaged as:
- AM combination pill (sodium salt 300 mg + estradiol + norethindrone acetate)
- PM sodium salt pill (sodium salt 300 mg only)
- A regimen goal of:
- achieving menstrual blood loss <80 mL/cycle and ≥50% reduction,
- preserving bone mineral density, at least in the claim-12/15 thresholds.
- Treatment of both:
- fibroid-associated HMB, and
- non-fibroid HMB due to adenomyosis (via claims 5-6).
For enforcement, a patent owner can focus on “use” conduct in clinical practice, including prescriber instructions and patient administration, and on product design when claims include dosage-form splitting.
What generic entry risks exist if a competitor tries to market an HMB regimen near this patent?
Risk surfaces by claim element
1) Same active and same salt at same exposure
If a competitor uses the same sodium salt (or a salt that does not literally meet “sodium salt” limitations), claim scope is tighter. If it uses different salts or prodrugs, it may avoid literal claim 1 depending on prosecution history and doctrine-of-equivalents positions (litigation-specific).
2) Same 600 mg/day free-acid equivalent
Any substantial deviation from 600 mg/day reduces direct match to the “amount equivalent to 600 mg per day of free acid” limitation.
3) Split dosing pattern
Claim 1 requires twice daily ~300 mg doses. Claim 10 recasts it as two dosage forms with daily AM/PM administration. Competitors can attempt:
- once-daily dosing (may avoid claim 1/10),
- different split ratios,
- different coordination timing for hormones.
4) Duration banding
A generic entrant whose label supports shorter duration and stops before a claimed minimum can reduce overlap against claims 1/2/7. But because the estate includes multiple windows and includes continuation up to 24 months (“as needed”), the duration design-around is constrained.
5) Outcomes and BMD performance thresholds
Even if the regimen is dosed similarly, failing to achieve <80 mL/cycle and ≥50% reduction would avoid method satisfaction, but competitors will target to meet endpoints. Similarly, bone-loss performance thresholds (<8% or <5%) create a leverage point tied to study and label claims.
How strong is the patent estate for 10,881,659 based on claim specificity (legal leverage and evidentiary burden)?
On “scope strength,” the claims are tight because they require:
- exact compound identity via chemical structure,
- sodium salt form,
- exact dosing equivalence,
- exact hormone doses,
- quantifiable efficacy thresholds,
- quantifiable BMD loss thresholds in dependent claims,
- specific duration minima and maxima in dependent claims,
- specific dosage-form structure in claim 10.
On “enforceability,” method claims with outcomes and administration schedules can still be strong because they align closely with how clinical trials and labeling are structured, and because regimen practice can be evidenced by study design, label language, prescriber protocols, and patient instruction. The outcome limitations also give the patentee a measurable compliance framework.
What litigation or Paragraph IV strategy would typically map to 10,881,659?
For a tri-drug method patent, challengers typically evaluate:
- whether they are accused of “use” of the method (as practiced) or “manufacture/sale” tied to a label that instructs the claimed use,
- whether their product labeling and dosing schedule would induce infringement of claims 1/7/10,
- whether their regimen meets the claimed efficacy and BMD thresholds.
The most direct challenge path is to contest literal match on one or more key claim elements:
- salt form,
- dose equivalence,
- schedule/dosage-form structure,
- duration band,
- outcome thresholds (clinical evidence),
- or population qualifier (fibroid vs non-fibroid vs adenomyosis).
Which competitors are most exposed (commercial geography and label-driven exposure)?
Exposure is driven by where a product is marketed and how the label instructs regimen duration, dosing schedule (AM/PM), and patient population (fibroid-associated HMB vs other HMB). Claims with dosage-form splitting can particularly raise exposure where commercial packaging matches claim 10’s AM/PM structure.
A key practical point: method-of-use claims can remain relevant even if a competitor’s formulation differs, as long as the regimen practice in the label and real-world administration satisfies the claim limitations.
Key Takeaways
- US 10,881,659 covers a specific oral tri-drug regimen for HMB: the claimed sodium salt dosed at 600 mg/day free-acid equivalent (300 mg twice daily) plus estradiol 1.0 mg/day and norethindrone acetate 0.5 mg/day.
- The patent is strongest where regimen practice is aligned to the claims’ duration thresholds (≥84 days; ≥168 days; windows around 168 days to 1 year), response endpoints (<80 mL/cycle and ≥50% reduction), and, in dependent claims, bone mineral density loss caps (<8% and <5%).
- The claim set includes both fibroid-associated HMB and non-fibroid HMB due to adenomyosis, and includes a specific two-dosage-form AM/PM construct (claim 10) that can create a packaging and dosing-algorithm infringement hook.
- Generic or alternative-regimen entrants face the highest risk when their labeling and dosing schedule match the claimed salt form, dose equivalence, regimen duration, and endpoint-oriented clinical framing.
FAQs
1) Does 10,881,659 require that menstrual blood loss fall below 80 mL per cycle?
Yes. Claim 1 and its dependent claim framework includes the requirement that the method reduces menstrual blood loss to <80 mL per cycle and by at least 50% from baseline.
2) What does claim 10 add versus the simpler dosing of claim 1?
Claim 10 adds a two-dosage-form AM/PM structure: an AM form containing 300 mg sodium salt plus estradiol and norethindrone acetate, and a PM form containing 300 mg sodium salt only.
3) Is bone mineral density protection part of the independent claim?
No. The BMD loss thresholds are in dependent claims: <8% (claim 12) and <5% (claim 15).
4) Can the regimen be used beyond 24 months?
Claim 16 caps continuation at not to exceed 24 months, even when described as “as needed.”
5) Are the hormone doses tied to once-daily administration?
In the fibroid-associated claims, yes: claim 7 specifies estradiol once daily and norethindrone acetate once daily, and claim 9 adds synchronization with one of the sodium-salt doses.
References (APA)
No sources were provided or cited beyond the claim text included in the prompt.
